Publicaciones (84) Publicaciones de MARÍA CONSUELO YOLANDA HUERTA ÁLVAREZ

2024

  1. Antithrombotic Use Patterns in COVID-19 Patients from Spain: A Real-World Data Study

    Journal of Clinical Medicine, Vol. 13, Núm. 8

  2. COVID-19 Distribution in Pregnancy, Drug Use Patterns and COVID-19 Medication during the Pandemic in Spain: Data from Real-World Electronic Health Records

    Pharmaceuticals, Vol. 17, Núm. 2

  3. Risk of ischemic stroke associated with direct oral anticoagulants discontinuation on patients with non-valvular atrial fibrillation

    Pharmacoepidemiology and Drug Safety, Vol. 33, Núm. 1

2023

  1. A Clinical Prediction Rule for Thrombosis in Critically Ill COVID-19 Patients: Step 1 Results of the Thromcco Study

    Journal of Clinical Medicine, Vol. 12, Núm. 4

  2. Background rates of 41 adverse events of special interest for COVID-19 vaccines in 10 European healthcare databases - an ACCESS cohort study

    Vaccine, Vol. 41, Núm. 1, pp. 251-262

  3. Effect of tramadol and DOACs with special attention to dabigatran on concomitant use, on the risk of mayor bleeding using BIFAP database in Spain

    Pharmacoepidemiology and Drug Safety, Vol. 32, Núm. 4, pp. 397-406

  4. Impact of 2018 EU Risk Minimisation Measures and Revised Pregnancy Prevention Programme on Utilisation and Prescribing Trends of Medicinal Products Containing Valproate: An Interrupted Time Series Study

    Drug Safety, Vol. 46, Núm. 7, pp. 689-702

  5. Impact of the 2018 revised Pregnancy Prevention Programme by the European Medicines Agency on the use of oral retinoids in females of childbearing age in Denmark, Italy, Netherlands, and Spain: an interrupted time series analysis

    Frontiers in Pharmacology, Vol. 14

2022

  1. Effect of regulatory interventions on agomelatine use in Spain: A multiple intervention time-series analysis in a nationwide electronic healthcare record database

    Pharmacoepidemiology and Drug Safety, Vol. 31, Núm. 3, pp. 294-301

  2. Flecainide and risk of skin neoplasms: Results of a large nested case–control study in Spain and Denmark

    Frontiers in Pharmacology, Vol. 13

  3. Myocarditis and pericarditis associated with SARS-CoV-2 vaccines: A population-based descriptive cohort and a nested self-controlled risk interval study using electronic health care data from four European countries

    Frontiers in Pharmacology, Vol. 13

  4. The Risk of SARS-CoV-2 Infection in Pregnant Women: An Observational Cohort Study Using the BIFAP Database

    Healthcare (Switzerland), Vol. 10, Núm. 12

  5. The role of prenatal exposure to antidepressants, anxiolytic, and hypnotics and its underlying illness on the risk of miscarriage using BIFAP database

    Pharmacoepidemiology and Drug Safety, Vol. 31, Núm. 8, pp. 901-912

  6. Thromboembolic Events in a Socio-Economically Disadvantaged Population with COVID-19 Admitted to a Medicalized Hotel in Madrid

    International Journal of Environmental Research and Public Health, Vol. 19, Núm. 13

2021

  1. A strategy for assessment and validation of major bleeding cases in a primary health care database in Spain

    Pharmacoepidemiology and Drug Safety, Vol. 30, Núm. 12, pp. 1696-1702

  2. A validation study on the frequency and natural history of miscarriages using the spanish primary care database bifap

    Healthcare (Switzerland), Vol. 9, Núm. 5

  3. Adherence to Direct Oral Anticoagulants in Patients With Non-Valvular Atrial Fibrillation: A Cross-National Comparison in Six European Countries (2008–2015)

    Frontiers in Pharmacology, Vol. 12

  4. Comparing risk of major bleeding between users of different oral anticoagulants in patients with nonvalvular atrial fibrillation

    British Journal of Clinical Pharmacology, Vol. 87, Núm. 3, pp. 988-1000

  5. Drug utilization study on immediate release Fentanyl in Spain. Prevalence, incidence, and indication

    Pharmacoepidemiology and Drug Safety, Vol. 30, Núm. 3, pp. 371-378

  6. Incidence Rates of Autoimmune Diseases in European Healthcare Databases: A Contribution of the ADVANCE Project

    Drug Safety, Vol. 44, Núm. 3, pp. 383-395